Table 2.
Difference in scoring systems between BRCA-positive and BRCA-negative using two independent t statistics: females
| Mean | Median | Range | t | p value | 95% CI | |
|---|---|---|---|---|---|---|
| Female (n = 285) | ||||||
| Age diagnosed with breast cancer (year) | ||||||
| Noncarriers | 44 | 44 | 18–82 | 1.48 | 0.14 | (−0.92, 6.51) |
| Carriers | 41.5 | 39 | 26–68 | |||
| Alla | 44 | 43.5 | 18–82 | |||
| Among carriers with breast cancer | ||||||
| BRCA1 | 38 | 36 | 26–68 | −1.75 | 0.089 # | (−12.35, 0.92) |
| BRCA2 | 44 | 41 | 28–63 | |||
| Age diagnosed with ovarian cancer (year) | ||||||
| Noncarriers | 34 | 31 | 19–50 | −2.38 | 0.039* | (−30.23, −0.97) |
| Carriers | 50 | 49 | 38–64 | |||
| Allb | 43.5 | 47.5 | 19–64 | |||
| Among carriers with ovarian cancer | ||||||
| BRCA1 | 50 | 48 | 38–64 | – | – | – |
| BRCA2 | 49 | 49 | 49 | |||
| BRCA 1 | ||||||
| Couch | ||||||
| BRCA negative | 10.55 | 7.7 | 0–77 | −3.04 | 0.004* | (−19.58, −3.95) |
| BRCA positive | 22.32 | 11.7 | 0–92.4 | |||
| All | 12.12 | 7.7 | 0–92.4 | |||
| Shattuck-Eidens | ||||||
| BRCA negative | 7.11 | 4.2 | 0–74.8 | −3.04 | 0.004* | (−16.71, −3.36) |
| BRCA positive | 17.14 | 8.05 | 1.2–85.9 | |||
| All | 8.44 | 4.6 | 0–85.9 | |||
| BRCAPRO | ||||||
| BRCA negative | 5.65 | 0.5 | 0–93.8 | −4 | <0.001* | (−33.41, −10.96) |
| BRCA positive | 27.84 | 9.7 | 0–98.8 | |||
| All | 8.61 | 0.8 | 0–98.8 | |||
| BOADICEA | ||||||
| BRCA negative | 4.37 | 1.17 | 0.03–90.07 | −3.67 | <0.001* | (−25.07, −7.26) |
| BRCA positive | 20.53 | 7.75 | 0.24–99.41 | |||
| All | 6.52 | 1.41 | 0.03–99.41 | |||
| BRCA 2 | ||||||
| BRCAPRO | ||||||
| BRCA negative | 4.55 | 1.2 | 0–61.4 | −3.12 | 0.003* | (−18.32, −3.91) |
| BRCA positive | 15.67 | 6.65 | 0–81.6 | |||
| All | 6.04 | 1.6 | 0–81.6 | |||
| BOADICEA | ||||||
| BRCA negative | 3.62 | 1.72 | 0.07–39.1 | −3.38 | 0.002* | (−11.71, −2.95) |
| BRCA positive | 10.95 | 6.5 | 0.04–59.98 | |||
| All | 4.59 | 1.82 | 0.04–59.98 | |||
| Any BRCA | ||||||
| Myriad II | ||||||
| BRCA negative | 9.75 | 6.8 | 2.8–53.9 | −3.66 | 0.001* | (−16.58, −4.79) |
| BRCA positive | 20.43 | 15.8 | 2.9–79 | |||
| All | 11.17 | 6.8 | 2.8–79 | |||
| BRCAPRO | ||||||
| BRCA negative | 10.19 | 2.5 | 0–99.2 | −5.54 | <0.001* | (−45.4, −21.12) |
| BRCA positive | 43.45 | 42.35 | 0–100 | |||
| All | 14.62 | 3.2 | 0–100 | |||
| BOADICEA | ||||||
| BRCA negative | 7.98 | 2.99 | 0.1–93.85 | −4.34 | <0.001* | (−34.45, −12.53) |
| BRCA positive | 31.48 | 14.79 | 1.07–99.84 | |||
| All | 11.12 | 3.4 | 0.1–99.84 | |||
aThere were five probands with ovarian cancer only, the number of patients with breast cancer is 280 (285-5)
bThere were 12 probands in total with ovarian cancer (hence 7 with breast and ovarian cancers): 5 (41.7%) of them were noncarriers, 6 (50%) were BRCA1, and 1 (8.3%) was BRCA2
# p < 0.1 (marginal significance); * p < 0.05